Table 2.
Characteristics of patients included in the study and the summary of the therapeutic approaches.
| A (n=103) | B (n=383) | C (n=90) | D (n=206) | E (n=41) | |
|---|---|---|---|---|---|
| Sex (male) | 48 (46.7%) | 206 (53.8%) | 60 (66.7%) | 115 (55.8%) | 19 (46.3%) |
| Age (Mean ± SD) | 63.62 ± 13.95 | 64.16 ± 14.53 | 61.16 ± 12.57 | 75.79 ± 11.36 | 64.05 ± 19.97 |
| Chronic ischemic heart disease | 34 (33.0%) | 162 (42.3%) | 23 (25.6%) | 144 (69.9%) | 19 (46.3%) |
| Hypertension | 65 (63.1%) | 270 (70.5%) | 63 (70.0%) | 179 (86.9%) | 25 (61.0%) |
| Diabetes | 29 (28.2%) | 120 (31.3%) | 34 (37.8) | 88 (42.7%) | 12 (29.3%) |
| Obesity | 20 (19.4%) | 140 (36.6%) | 42 (46.7%) | 63 (30.6%) | 9 (22.0%) |
| Arrhythmia | 15 (14.6%) | 70 (18.3%) | 6 (6.7%) | 62 (30.1%) | 14 (34.1%) |
| Bronchial asthma | 12 (11.7%) | 36 (9.4%) | 4 (4.4%) | 19 (9.2%) | 2 (4.9%) |
| Chronic obstructive pulmonary disease | 10 (9.7%) | 44 (11.5%) | 8 (8.9%) | 33 (16.0%) | 3 (7.3%) |
| Thyroid gland disease | 8 (7.8%) | 65 (17.0%) | 13 (14.4%) | 39 (18.9%) | 6 (14.6%) |
| Chronic kidney disease | 18 (17.5%) | 59 (15.4%) | 12 (13.3%) | 73 (35.4%) | 10 (24.4%) |
| Dyslipidemia | 36 (35.0%) | 141 (36.8%) | 27 (30.0%) | 84 (40.8%) | 10 (24.4%) |
| Stroke history | 9 (8.7%) | 27 (7.0%) | 9 (10.0%) | 38 (18.4%) | 5 (12.2%) |
| Cancer | 15 (14.6%) | 21 (5.5%) | 5 (5.6%) | 30 (14.6%) | 10 (24.4%) |
| Hematological malignancy | 2 (1.9%) | 6 (1.6%) | 2 (2.2%) | 12 (5.8%) | 1 (2.4%) |
| Interstitial lung disease | 1 (0.97%) | 6 (1.6%) | 1 (1.1%) | 7 (3.4%) | 2 (4.9%) |
| Autoimmunity | 7 (6.8%) | 24 (6.3%) | 6 (6.7%) | 20 (9.7%) | 3 (7.3%) |
| Immunodeficiency | 1 (0.97%) | 3 (0.78%) | 5 (5.6%) | 3 (1.5%) | 0 |
| Cirrhosis | 0 | 0 | 0 | 4 (1.9%) | 2 (4.9%) |
| Pregnancy | 0 | 2 (0.52%) | 3 (3.3%) | 0 | 1 (2.4%) |
| Venous thromboembolism (during COVID-19) | 7 (6.8%) | 20 (5.2%) | 5 (5.6%) | 7 (3.4%) | 0 |
| Therapeutic approaches | |||||
| Systemic corticosteroids | 45 (43.7%) | 344 (89.8%) | 86 (95.6%) | 177 (85.9%) | 15 (36.6%) |
| Antivirals (remdesivir, favipiravir) | 13 (12.6%) | 146 (38.1%) | 38 (42.2%) | 70 (34.0%) | 4 (9.8%) |
| Baricitinib | 4 (3.9%) | 28 (7.3%) | 15 (16.7%) | 16 (7.8%) | 0 |
| Tocilizumab | 0 | 1 (0.3%) | 4 (4.4%) | 3 (1.5%) | 0 |
| Anakinra | 0 | 1 (0.3%) | 2 (2.2%) | 0 | 0 |